Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ: JAGX )

0.8451 -0.0145 (-1.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
Via ACCESSWIRE
Jaguar Health to Present November 1st at Emerging Growth Conference
Via ACCESSWIRE
Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
Via ACCESSWIRE
Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
Via ACCESSWIRE
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Via ACCESSWIRE
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
Via ACCESSWIRE
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
Via ACCESSWIRE
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESSWIRE
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
Via ACCESSWIRE
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
Via ACCESSWIRE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Via ACCESSWIRE
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
Via ACCESSWIRE
Jaguar Health Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Via ACCESSWIRE
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
Via ACCESSWIRE
BioMedNewsBreaks – Jaguar Health Inc. (NASDAQ: JAGX) Announces Investor Engagement Campaign with B2i Digital
Via Investor Brand Network
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
Via ACCESSWIRE
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Via ACCESSWIRE
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Via ACCESSWIRE
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
Via ACCESSWIRE
REMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.